**1. Introduction**

One of the actual problems of modern medicine is the views and approaches to wound healing, depending on the cause of wounds.

They are numerous, especially depending on the effect of bacteria, such as aerobic and anaerobic, viruses, fungi, injuries to the skin due to burns, and various chemical and physical factors, such as low temperature [1].

In recent years, difficulties in wound healing have been observed mainly due to the ineffectiveness of various widely used antimicrobials, especially antibiotics. It is more severe if it develops against some existing somatic diseases, such as diabetes and non-diabetes mellitus, some acquired connective tissue diseases, congenital and acquired immune deficiencies, etc. The search and development for new effective means of symptomatic-pathogenic treatment of wounds are one of the priorities of modern medicine.

In connection with this, it becomes expedient to carry out pharmacokinetic research to find out the ability of the components of the given composition to remain in the wound.

Studies show that the pharmacokinetics of Eflornithine rats are characterized by a slow systemic blood flow after co-administration of Eflornithine paste to rats, providing a pronounced restorative effect on the wound surface than with Eflornithine alone.

Wound healing has always been fraught with difficulties, as the use of a wide range of antibacterial drugs, including antibiotics, has often been ineffective due to the polymorphic nature of the bacteria found in the wound.

The search for new effective antimicrobials for wound healing, including the development of new formulations the ingredients of which may have a multifaceted inhibitory effect on the growth of bacteria in the wound, is still a very promising direction in modern medicine.

In this regard, Armenicum (ointment and paste) exhibits significant cytotoxic effects on a number of resident conditionally pathogenic bacteria [1, 2].

The authors attribute the effects of "Armenicum" quite well to iodine, which has a direct and/or mediated bactericidal effect by stimulating the activity of radicals in the wounds of diseased tissues [1, 3–6].

The new composition "Eflornithine–Armenicum" has been developed by taking into account the new scientific interpretations that have appeared in the inflammatory processes of wounds during the last 10 years, which are given below:


Using the results of modern scientific research for the treatment of wounds, we found it expedient to develop the drug composition "Eflornithine–Armenicum", which will be characterized by access restriction of polyamines to microorganisms.

The inclusion of Eflornithine in the composition of the Armenicum will inhibit diabetes and non-diabetes mellitus bacterial persistence in the earliest stages of the local inflammatory process, which will probably lead to a faster and earlier woundhealing process.

It should be noted that pharmacological examinations should be mandatory for the approbation of the therapeutic efficacy of the "Eflornithine–Armenicum" composition on the wound model.

Eflornithine human racemic pharmacokinetics are characterized by an oral bioavailability of approximately 50%, mainly renal elimination (>80%) of low extraction, no reported metabolites, negligible plasma protein binding, and a multiphasic plasma concentration-time profile, probably contributing to highly varying estimates

### *Comparison of the Pharmacokinetics of Eflornithine after Application of Eflornithine Cream… DOI: http://dx.doi.org/10.5772/intechopen.105742*

of half-life ranging from 2 to 30 h and percutaneous absorption of topical applications of Eflornithine hydrochloride (HCl) cream is very low (<1%). Absorbed Eflornithine is rapidly eliminated from plasma and predominantly excreted in urine without being metabolized. While the percutaneous absorption of Eflornithine increased after twice-daily topical application, relative to the first application, absorption reached a steady state within four days of twice-daily application and remained low. Trough plasma concentrations also remained constant after four days of twice-daily application. Systemic exposure was low, with steady-state peak and trough plasma concentrations during twice-daily treatment of 10 and 5 ng/ml, respectively, and the terminal half-life averaged 8 to 11 hours. The low degree of percutaneous absorption and low systemic exposure to Eflornithine offer a favorable clinical safety profile of Eflornithine HCl 13.9% cream [7–9].

The results of the pharmacokinetics study of Armenicum paste following its application on wound surface in two doses showed that the pharmacokinetics of the major active ingredient of Armenicum paste was characterized by slow absorption into the blood and remained on the wound surface for a long time providing more pronounced pharmacological effect [6].

It should be noted that pharmacological studies should serve as an obligatory stage in testing the therapeutic efficacy of the "Eflornithine–Armenicum" composition on a wound model. For this purpose, we carried out pharmacokinetic studies of the medicinal composition created by us on the basis of the pharmacological company "Arpimed" (Armenia) in order to determine the duration of its stay on the wound surface and the rate of absorption from the wounds into the bloodstream.
